Cytomegalovirus Prophylaxis With Intravenous Polyvalent Immunoglobulin in High-Risk Renal Transplant Recipients

Leroy, Fanny; Séchet, A.; Ayache, Ramzi Abou; Thierry, Antoine; Belmouaz, Simohamed; Desport, Éstelle; Bauwens, Marc; Bridoux, Frank; Touchard, Guy

doi:10.1016/j.transproceed.2006.07.001

Cited by 17 publications

(9 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The efficacy of low‐dose valaciclovir (3000 mg/day) was suggested by two small retrospective renal transplant studies, where the incidence of CMV disease was 8.5% at 6 months 14 and 24% at 3 years, 15 respectively. CMVIg, administered as monotherapy or in combination with antiviral agents, also reduces the incidence of CMV disease by up to 75% in renal transplant recipients 16–19,27–29 and a meta‐analysis of CMVIg in SOT showed a significant reduction in CMV disease, CMV‐related deaths and all‐cause mortality 17 …”

Section: Discussionmentioning

confidence: 99%

Low‐dose valaciclovir and cytomegalovirus immunoglobulin to prevent cytomegalovirus disease in high‐risk renal transplant recipients

et al. 2010

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Low‐dose valaciclovir and cytomegalovirus immunoglobulin to prevent cytomegalovirus disease in high‐risk renal transplant recipients

et al. 2010

View full text Add to dashboard Cite

show abstract

“…In fact, several studies have reported the successful prevention of CMV disease in high-risk transplant recipients using passive immunization [26][27][28].…”

Section: Discussionmentioning

confidence: 99%

Association of the Outcome of Renal Transplantation with Antibody Response to Cytomegalovirus Strain--Specific Glycoprotein H Epitopes

Ishibashi

Tokumoto

Tanabe

et al. 2007

Clinical Infectious Diseases

View full text Add to dashboard Cite

Background. Cytomegalovirus (CMV) is the most important pathogen affecting the outcome of renal transplantation. The combination of CMV-seronegative transplant recipients with CMV-seropositive transplant donors places recipients at the highest risk of CMV disease. In cases of congenital CMV infection, existing immunity only partially protected mothers from reinfection with a different genotypic strain. The effect of differences in infected CMV strains between CMV-seropositive transplant donors and CMV seropositive transplant recipients on the outcome of transplantation remains unclear.Methods. In this prospective multicenter study, the presence of antibodies against strain-specific glycoprotein H epitopes in 84 CMV-seropositive transplant donor/CMV-seropositive transplant recipient renal transplantation cases were determined, and their relationships to acute transplant rejection, CMV infection, degree of antigenemia, and CMV disease were evaluated.Results. Among the 84 donor/recipient pairs, 45 and 32 had matched and mismatched strain-specific glycoprotein H antibodies, respectively. Acute transplant rejection in the mismatched group was more frequent than it was in the matched group (63% vs. 22%;). CMV disease was also more frequently observed in the P p .005 mismatched group (28% vs. 9%;). The mismatched group had a higher level of antigenemia ( P p .026 P p ). .019Conclusions. Our results illustrate more adverse events in the cases with a CMV-seropositive transplant donor and a CMV-seropositive transplant recipient in which the glycoprotein H antibodies are mismatched, suggesting that reinfection with a different CMV strain results in more complications.

show abstract

“…therapy for rejection (1,2). After solid organ engraftment, approximately 75% of recipients have evidence of active CMV infection within the ¢rst year post transplantation (3), either experiencing de novo infection or undergoing reactivation of latent CMV (4).…”

mentioning

confidence: 99%

Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil inde novocardiac transplant recipients: a randomized, multicenter study

Viganò

Dengler

Mattei

et al. 2010

Transplant Infectious Disease

View full text Add to dashboard Cite

Cytomegalovirus (CMV) is a major cause of infectious complications following cardiac transplantation, severely affecting short- and long-term outcomes. A 12-month, multicenter, randomized, open-label study in de novo cardiac transplant patients was undertaken to compare the efficacy, renal function, and safety of everolimus plus reduced cyclosporine versus mycophenolate mofetil (MMF) plus standard cyclosporine (ClinicalTrials.gov NCT00150046). CMV-specific data was prospectively collected on infections, laboratory evidence, CMV syndrome, and CMV disease. In total, 176 patients were randomized (everolimus 92; MMF 84). Use of CMV prophylaxis was similar between groups (everolimus 20.8%; MMF 24.0%). Patients in the everolimus arm had a significantly lower incidence of any CMV event (8.8% versus 32.5% with MMF, P<0.001), CMV infection as an adverse event (4.4% versus 16.9%, P=0.011), laboratory evidence of CMV (antigenemia 7.7% versus 27.7%, P<0.001; polymerase chain reaction assay 2.2% versus 12.0%, P=0.015), and CMV syndrome (1.1% versus 8.4%, P=0.028). In the donor (D)+/recipient (R)+and D-/R+ subgroups, even after adjusting for use of prophylaxis, the CMV event rate remained significantly lower with everolimus than with MMF (P=0.0015 and P=0.0381, respectively). In conclusion, de novo cardiac transplant recipients experienced lower rates of CMV infection, CMV syndrome, or organ involvement on an everolimus-based immunosuppressant regimen compared with MMF.

show abstract

Cytomegalovirus Prophylaxis With Intravenous Polyvalent Immunoglobulin in High-Risk Renal Transplant Recipients

Cited by 17 publications

References 5 publications

Low‐dose valaciclovir and cytomegalovirus immunoglobulin to prevent cytomegalovirus disease in high‐risk renal transplant recipients

Low‐dose valaciclovir and cytomegalovirus immunoglobulin to prevent cytomegalovirus disease in high‐risk renal transplant recipients

Association of the Outcome of Renal Transplantation with Antibody Response to Cytomegalovirus Strain--Specific Glycoprotein H Epitopes

Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil inde novocardiac transplant recipients: a randomized, multicenter study

Contact Info

Product

Resources

About